INDEVUS COMPLETES ENROLLMENT IN SANCTURA STUDY

A A

Indevus Pharmaceuticals has completed enrollment in a Phase III trial for Sanctura XR, the company's once-daily formulation of Sanctura, a treatment for overactive bladder.

The trial has enrolled over 560 patients and the company anticipates reporting results in July of 2006. Both Phase III trials are 12-week, double-blind, placebo-controlled studies, evaluating the effect of Sanctura XR in reducing frequency, urgency, and incontinence episodes in patients with overactive bladder.